What Is Alpha-Hydroxyalprazolam on a Drug Test?

Alpha-hydroxyalprazolam is the main breakdown product your body creates after you take alprazolam, the benzodiazepine sold under the brand name Xanax. When a drug test reports alpha-hydroxyalprazolam, it is confirming that alprazolam was in your system and that your liver processed it in the expected way. In most urine samples, alpha-hydroxyalprazolam appears at a higher concentration than the parent drug itself, which is why labs specifically target it as the key marker of alprazolam use.

How Alpha-Hydroxyalprazolam Forms in Your Body

After you swallow an alprazolam tablet, the drug travels to your liver, where a family of enzymes called CYP3A breaks it down. Two main metabolites result from this process: alpha-hydroxyalprazolam and 4-hydroxyalprazolam. The enzyme CYP3A5 is the major producer of alpha-hydroxyalprazolam, while CYP3A4 and CYP3A5 together are responsible for most of the 4-hydroxyalprazolam that forms.¹ A third pathway in the liver produces a further breakdown compound with a longer chemical name, but it is alpha-hydroxyalprazolam that dominates in urine and matters most for testing.²

Alpha-hydroxyalprazolam retains some pharmacological activity, meaning it still acts on the same receptors in the brain that alprazolam does, though more weakly. This is worth knowing because even after the original drug has largely cleared from your blood, its metabolite continues circulating and contributing to sedation and other effects. The body eventually attaches a sugar molecule to the metabolite (a process called conjugation), making it water-soluble enough to be filtered by the kidneys and excreted in urine.

Why Labs Target the Metabolite, Not Just the Parent Drug

If you are wondering why a drug test names alpha-hydroxyalprazolam instead of simply saying “alprazolam detected,” it comes down to concentration. Alprazolam is prescribed in small doses, often fractions of a milligram, and the parent drug clears from the bloodstream relatively quickly. By the time a urine sample is collected, the unchanged drug may be present at very low levels or not at all. Alpha-hydroxyalprazolam, on the other hand, accumulates in urine at much higher concentrations and persists longer. One early study developing a urine confirmation method found that alpha-hydroxyalprazolam was present in the highest concentration and separated most cleanly from other substances naturally found in urine.²

In a study examining 13 human urine specimens that screened positive for benzodiazepines, alpha-hydroxyalprazolam was found in seven of them, with concentrations ranging from roughly 49 to over 1,260 ng/mL.³ That wide range reflects differences in dose, timing of the last dose, and individual metabolism. The point is that alpha-hydroxyalprazolam gives the lab a much larger analytical target to hit than trying to detect trace quantities of unchanged alprazolam.

How Drug Testing Actually Works for Benzodiazepines

Most workplace and clinical drug tests use a two-step process. The first step is an immunoassay screen, which is fast and inexpensive but designed to detect an entire class of drugs, not a specific one. Standard immunoassays for benzodiazepines are calibrated to detect compounds like oxazepam and nordiazepam quite well, but they are notoriously poor at picking up alprazolam and its metabolites. Alprazolam is what toxicologists call a “low cross-reactivity” benzodiazepine for many commercial immunoassay kits. This means a person taking therapeutic doses of alprazolam can produce a negative screening result even though the drug is genuinely in their system.

When the initial screen is positive, or when a lab is specifically ordered to look for alprazolam, the sample moves to confirmation testing. Confirmation typically uses chromatographic techniques coupled with mass spectrometry, which can identify individual compounds at very low concentrations. Before running the confirmation, labs must first break apart the conjugated form of alpha-hydroxyalprazolam using an enzyme called beta-glucuronidase. This enzymatic hydrolysis step frees the metabolite so the instrument can detect it.⁴ If the hydrolysis step is skipped or performed poorly, the test can undercount how much metabolite is actually present, potentially turning a true positive into a false negative.

More advanced methods, such as liquid chromatography-tandem mass spectrometry, can detect alpha-hydroxyalprazolam at concentrations as low as 0.05 ng/mL, which is 40 to 100 times lower than typical reference ranges.⁵ That level of sensitivity is more than what standard clinical testing requires, but it matters in forensic and research settings where every trace counts.

Can Other Drugs Produce Alpha-Hydroxyalprazolam?

This is a question people understandably ask when alpha-hydroxyalprazolam shows up on a test and they insist they did not take Xanax. The honest answer is that there is at least one other pharmaceutical that can produce this metabolite, though it is uncommon. Adinazolam, a benzodiazepine that was investigated as an antidepressant but never widely marketed, breaks down in the body to form alpha-hydroxyalprazolam as a minor metabolite.⁶ Adinazolam’s primary breakdown product is N-desmethyladinazolam, with alpha-hydroxyalprazolam appearing in smaller quantities. In practice, adinazolam is not available in most countries and is rarely encountered, so this cross-reactivity pathway is more of a theoretical curiosity than a common explanation for a positive result.

Beyond adinazolam, no other mainstream prescription drug is known to produce alpha-hydroxyalprazolam. However, the rise of illicit designer benzodiazepines complicates the picture somewhat. Some novel benzodiazepines sold on the black market have chemical structures close enough to alprazolam that they could, in theory, share metabolic pathways. Whether those compounds produce alpha-hydroxyalprazolam specifically depends on their exact chemistry. If you are facing a confirmed positive for alpha-hydroxyalprazolam on a drug test, the overwhelmingly likely explanation is that alprazolam entered your body, whether through a prescription, from someone else’s medication, or unknowingly through a contaminated substance.

What Affects How Long Alpha-Hydroxyalprazolam Stays Detectable

There is no single detection window that applies to everyone. The range people commonly hear quoted for alprazolam in urine is roughly one to five days after the last dose, but several factors push that window shorter or longer.

Dose and frequency: Someone taking 0.25 mg occasionally will clear the metabolite faster than someone taking 2 mg multiple times a day for weeks. Chronic use leads to accumulation, and the metabolite can linger in urine for longer after the last dose.
Liver enzyme activity: Because CYP3A5 is the major producer of alpha-hydroxyalprazolam, people with genetically higher or lower CYP3A5 activity will metabolize the drug at different rates.¹ Ethnic background plays a role here, as CYP3A5 expression varies across populations.
Drug interactions: Medications or substances that inhibit CYP3A enzymes slow the breakdown of alprazolam. The antifungal drug ketoconazole, for instance, is a potent inhibitor of alprazolam hydroxylation.⁷ Certain antidepressants that affect serotonin reuptake can also slow the process. When metabolism is inhibited, the parent drug hangs around longer and higher levels of both alprazolam and alpha-hydroxyalprazolam can persist.
Body composition and hydration: General factors like body fat percentage, kidney function, and how much water you drink all influence urinary drug concentrations, though these effects are harder to quantify precisely.

The concentration range seen across individuals is wide. The study mentioned earlier found alpha-hydroxyalprazolam levels ranging from 49 to 1,264 ng/mL across just seven samples.³ A more than 25-fold difference between the lowest and highest concentrations gives you a sense of how variable the result can be from one person to the next.

What a Positive Result Does and Does Not Tell You

A confirmed detection of alpha-hydroxyalprazolam tells the lab that alprazolam was in the person’s body and was metabolized normally. It does not, by itself, tell anyone when the drug was taken, what the dose was, or whether the person was impaired at the time the sample was collected. The relationship between a urine concentration and actual impairment is loose at best, because urine accumulates drug metabolites over hours and the concentration depends heavily on how dilute or concentrated the sample is.

Blood testing gets closer to answering the impairment question, since blood levels reflect what is circulating in the body at the moment the sample is drawn. But even blood levels require careful interpretation. Tolerance develops with regular benzodiazepine use, so two people with the same blood concentration of alprazolam can look very different in terms of sedation and functioning.

For employment drug tests, the practical question is usually binary: was the drug present or not? If you have a valid prescription for alprazolam, a positive result for alpha-hydroxyalprazolam is expected and can typically be explained to a Medical Review Officer (the physician who reviews workplace drug test results). The MRO will verify your prescription before reporting the result to your employer. If you do not have a prescription, a confirmed positive is treated like any other non-prescribed controlled substance finding.

Why Alprazolam Is Harder to Catch Than Many Other Benzodiazepines

People sometimes assume that all benzodiazepines are equally easy to detect, but that is not the case. Older, longer-acting benzodiazepines like diazepam (Valium) produce metabolites such as oxazepam and nordiazepam that are very reliably picked up by standard immunoassay screens. These screens were essentially designed around those metabolites. Alprazolam, being a triazolobenzodiazepine with a different chemical backbone, does not cross-react as strongly with the antibodies used in those kits. The result is that standard screening panels miss alprazolam use more often than they miss diazepam or chlordiazepoxide use.

This is one reason forensic and clinical labs developed confirmation methods specifically targeting alpha-hydroxyalprazolam alongside alpha-hydroxytriazolam (the corresponding metabolite of triazolam, another triazolobenzodiazepine). These metabolites need to be confirmed individually using chromatography and mass spectrometry rather than relying on the class-wide immunoassay screen.³ If your drug test panel only uses an immunoassay without a specific alprazolam confirmation add-on, therapeutic use of alprazolam could go undetected.

Next-Day Effects and the Gap Between Feeling Fine and Testing Positive

An uncomfortable reality of alprazolam use is that you can feel subjectively normal while the drug and its metabolites are still very much present in your body. A study of healthy adults found that a single 1 mg dose of alprazolam taken at bedtime produced measurable impairment in simulated driving performance roughly eight and a half hours later, even though participants did not report feeling sedated or impaired. A 2 mg dose impaired driving for up to about 13 and a half hours after the dose.⁸ This disconnect between self-perception and actual performance is relevant for anyone who takes alprazolam in the evening and drives or operates equipment the next morning.

The metabolite alpha-hydroxyalprazolam will of course be present in urine throughout this period and well beyond it. The key point is that a positive drug test result can coincide with genuine functional impairment even if the person taking the test feels fine. This also matters in workplace accident investigations, where a positive urine result might be used as evidence of possible impairment, and the tested individual needs to understand that the science does support residual effects lasting well into the next day.

Forensic and Long-Term Specimen Testing

Alpha-hydroxyalprazolam is not only relevant for standard urine drug testing. It plays a role in forensic investigations involving older or unusual specimens. One validated method demonstrated the ability to detect and quantify both alprazolam and alpha-hydroxyalprazolam in dried blood spot samples that had been stored for 17 years, achieving limits of detection as low as 0.05 ng/mL.⁵ Dried blood spots are collected by placing a few drops of blood on filter paper, and they are sometimes the only biological evidence available in cold cases or medical examiner reviews.

The fact that alpha-hydroxyalprazolam remains identifiable in a dried sample stored for nearly two decades speaks to the chemical stability of the compound and to the power of modern analytical instruments. For family members involved in wrongful death cases, sexual assault investigations, or other proceedings where benzodiazepine involvement is suspected, knowing that alpha-hydroxyalprazolam can be recovered from archived samples long after the event is genuinely important information. It means a case is not necessarily closed simply because years have passed and traditional blood or urine samples were never collected.

The Role of Genetic Variation in Metabolism

Not everyone breaks down alprazolam at the same rate, and genetic differences in liver enzymes are the main reason. The CYP3A subfamily includes four members in humans, and two of them do most of the heavy lifting for alprazolam. CYP3A4 is the most abundant liver enzyme and preferentially produces 4-hydroxyalprazolam. CYP3A5, when it is expressed, is the primary source of alpha-hydroxyalprazolam.⁹

Here is why that matters: a significant portion of people carry a genetic variant that makes their CYP3A5 enzyme essentially nonfunctional. These individuals still metabolize alprazolam through CYP3A4 and other pathways, but the ratio of alpha-hydroxyalprazolam to 4-hydroxyalprazolam in their urine can shift. In theory, a person who produces less alpha-hydroxyalprazolam because of a CYP3A5 variant might fall below a lab’s detection cutoff sooner than someone with fully active CYP3A5. The less common enzyme CYP3A43, which is expressed at high levels in the brain rather than the liver, also contributes to alpha-hydroxyalprazolam production, though at much lower rates.¹ Mutations in CYP3A43 can further alter the metabolic profile.

Pharmacogenomic testing, which identifies these genetic variants, is not standard practice before prescribing alprazolam. But it is increasingly available and could eventually help explain why some patients seem to metabolize the drug unusually quickly or slowly. For drug-testing purposes, genetic variation mostly affects how long the metabolite remains detectable and in what concentration, not whether it forms at all. If alprazolam enters your body, alpha-hydroxyalprazolam will be produced. The question is how much and for how long.